| INDEPENDENT-THIRD-PARTY |
INDEPENDENT-THIRD-PARTY |
92%
|
In 2025, the Group transferred its royalty rights to an independent third party for a fixed upfront cash consideration. |
| AMGN |
Amgen Inc. |
90%
|
For the three months ended March 31, 2026 and 2025, the Company’s other revenue consisted primarily of royalty revenue from IMDELLTRA ® sales outside of China under the Amgen collaboration agreement |
| AMGN |
Amgen Inc. |
90%
|
Reciprocal relationship from AMGN graph: Reciprocal relationship from ONC graph: Reciprocal relationship from AMGN graph: Reciprocal relationship from ONC graph: Reciprocal relationship from AMGN gra… |
| NVS |
Novartis AG |
80%
|
Reciprocal relationship from NVS graph: Reciprocal relationship from ONC graph: For the three months ended March 31, 2026 and 2025, the Company’s other revenue consisted primarily of royalty revenue … |
| NVS |
Novartis AG |
80%
|
For the three months ended March 31, 2026 and 2025, the Company’s other revenue consisted primarily of royalty revenue from IMDELLTRA ® sales outside of China under the Amgen collaboration agreement |
| FISI |
Financial Institutions, Inc. |
72%
|
Reciprocal relationship from FISI graph: Reciprocal relationship from ONC graph: Reciprocal relationship from FISI graph: Reciprocal relationship from ONC graph: tors could materially and adversely a… |
| FISI |
Financial Institutions, Inc. |
72%
|
tors could materially and adversely affect our business, financial condition, results of operations, and prospects, and could reduce the value of, and any dividends payable on, our shares in foreign … |
| ALTHOUGH-BEONE-MEDICINES-LTD |
ALTHOUGH-BEONE-MEDICINES-LTD |
62%
|
mmercial or clinical supply of our medicines and drug candidates could be negatively impacted due to reduced operations or a shutdown of our or our third-party manufacturing facilities, distribution … |
| BEIGENE-LTD |
BEIGENE-LTD |
62%
|
. As of March 31, 2026, the remaining capital commitment was $ 4,406 and is expected to be paid from time to time over the investment period. 17. Segment and Geographic Information The Company operat… |
| BEONE-MEDICINES-LTD |
BEONE-MEDICINES-LTD |
62%
|
mmercial or clinical supply of our medicines and drug candidates could be negatively impacted due to reduced operations or a shutdown of our or our third-party manufacturing facilities, distribution … |
| BEONE-MEDICINES-USA-INC |
BEONE-MEDICINES-USA-INC |
62%
|
tors could materially and adversely affect our business, financial condition, results of operations, and prospects, and could reduce the value of, and any dividends payable on, our shares in foreign … |
| CAPITAL-RESOURCES |
CAPITAL-RESOURCES |
62%
|
t leverage ratio of not greater than 2.50 to 1.00; (iii) a minimum total consolidated shareholders’ equity of the Group of not less than $2.7 billion; (iv) a minimum cash balance held outside the PRC… |
| CONTROLLED-FOREIGN-CORPORATION |
CONTROLLED-FOREIGN-CORPORATION |
62%
|
mmercial or clinical supply of our medicines and drug candidates could be negatively impacted due to reduced operations or a shutdown of our or our third-party manufacturing facilities, distribution … |
| HONG-KONG-CO-LIMITED |
HONG-KONG-CO-LIMITED |
62%
|
mmercial or clinical supply of our medicines and drug candidates could be negatively impacted due to reduced operations or a shutdown of our or our third-party manufacturing facilities, distribution … |
| HONG-KONG-LIMITED |
HONG-KONG-LIMITED |
62%
|
in sanctions being imposed on us, including fines, injunctions, civil penalties, a requirement to suspend or put on hold one or more of our clinical trials, failure of regulatory authorities to grant… |
| NOVARTIS-PHARMA-AG |
NOVARTIS-PHARMA-AG |
62%
|
n, sales and use of ABRAXANE in China previously supplied to us by BMS, and the drug was subsequently recalled by BMS. This suspension was based on inspection findings at BMS’s contract manufacturing… |
| SHIJIAZHUANG-CO-LTD |
SHIJIAZHUANG-CO-LTD |
62%
|
n, sales and use of ABRAXANE in China previously supplied to us by BMS, and the drug was subsequently recalled by BMS. This suspension was based on inspection findings at BMS’s contract manufacturing… |
| ZYDUS-LIFESCIENCES-LIMITED |
ZYDUS-LIFESCIENCES-LIMITED |
62%
|
tors could materially and adversely affect our business, financial condition, results of operations, and prospects, and could reduce the value of, and any dividends payable on, our shares in foreign … |
